In this interview, industry experts Mathieu Bennet and Dustin Whitson explore how automation and single-cell technologies are transforming high-throughput B-cell cloning for antibody discovery. Can ...

B cell development in swine presents a unique model within mammalian immunology. In contrast to traditional murine and human systems, swine exhibit notable differences in the temporal order of heavy ...

Findings published today in Nature Cancer from Charles Mullighan, MBBS (Hons), MSc, MD, deputy director of the St. Jude Comprehensive Cancer Center, Department of Pathology, and collaborators show ...

Antengene grants UCB worldwide exclusive rights to develop, manufacture and commercialize ATG-201, a CD19/CD3 bispecific T-cell engager (TCE) antibody, targeting B cell-related autoimmune ...

New findings show that the stage of normal cell development at which B cells transform into leukemic cells impacts treatment outcomes for pediatric patients with B-cell acute lymphoblastic leukemia (B ...

T-bet expression is required for persistence of memory B cells that have rapid differentiation potential to become antibody-producing plasma cells in response to a second infection BIRMINGHAM, Ala. – ...

Germinal center B-cell–like diffuse large B-cell lymphomas (GCB-DLBCLs) show dependence on DOT1L and EZH2, with combined targeting offering potential as an alternative differentiation-based therapy.

UCB secured worldwide exclusive rights to develop, manufacture, and commercialize ATG-201, including access to Antengene’s enabling manufacturing technology for this bispecific T-cell engager modality ...